BARCELONA, Spain — Results from the cardiovascular-safety trials of the type 2 diabetes drugs, EXAMINE with alogliptin (Nesina, Takeda Pharmaceuticals) and SAVOR-TIMI 53 with saxagliptin (Onglyza, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results